New Book 'Conquering COVID-19: Sinovac, An Unlikely Hero' Out February 1

BOSTON – A new book telling the rough-and-tumble rise of China’s Sinovac Biotech (NASDAQ: SVA) will be published on February 1.

Sinovac plans to manufacture 1 billion doses of its COVID-19 vaccine, CoronaVac, this year, making it one of the top producers in the world.

The author, fund manager Peter Halesworth, has witnessed Sinovac’s rise to the forefront of the fight against COVID-19. Despite the ups and downs portrayed in the book, Sinovac is now seen as a major ally in the global fight against the pandemic. The company also displays China’s scientific prowess by supplying nations across three continents with CoronaVac.

Highlights of “Conquering COVID” include:

• How Sinovac’s experience in the early 2000s with SARS (Severe Acute Respiratory Syndrome) positioned it for its relative, COVID-19, today.
• How Sinovac, once ignored by Wall Street, is being transformed by COVID-19.
• How a battle for control of Sinovac has frozen the company’s value during an incredible bull run in COVID-19 vaccine stocks

A website for the book is available via this link: https://www.sinovacbook.com

Any questions about the book “Conquering COVID” should be sent to [email protected]

You May Also Be Interested In

• Amazon's Zoox, Alphabet's Waymo expand robotaxi services to more US cities
• Goldman Sachs starts Viridien at Buy on exploration recovery, shares rise
• Why JPM thinks rising bond yields won’t derail the equity rally